Proteome profiling of formalin-fixed, paraffin-embedded lung adenocarcinoma tissues using a tandem mass tag-based quantitative proteomics approach.
bioinformatics analysis
formalin-fixed
lung adenocarcinoma
novel biomarkers
paraffin-embedded tissues
tandem mass tag-based quantitative proteomics
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
29
03
2021
accepted:
22
06
2021
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
31
8
2021
Statut:
ppublish
Résumé
Over the past few decades, increasing efforts have been made to improve the understanding of, and treatment options for, lung adenocarcinoma (LUAD). However, considering the heterogeneity of LUAD, precise proteomics-based characterization at the molecular level is an urgent clinical requirement for effective treatment. Formalin-fixed, paraffin-embedded (FFPE) tissue is a good option as the working tool for proteomics studies. The present study aimed to obtain a global protein profile using LUAD FFPE tissue samples. Using a quantitative proteomics approach, the study revealed that 360 proteins were significantly more highly expressed in LUAD than in adjacent nontumor lung tissues. Also, 19 differentially expressed membrane proteins were found to be primarily responsible for immune processes. Epidermal growth factor (EGF)-like domain and laminin EGF domain showed markedly different expression levels between cancer tissues and tumor-adjacent normal tissues. Furthermore, Gene Ontology functional enrichment analysis showed that significantly upregulated proteins were associated with the endoplasmic reticulum lumen, protein disulfide isomerase activity, vitamin binding, cell cycle G
Identifiants
pubmed: 34457061
doi: 10.3892/ol.2021.12967
pii: OL-0-0-12967
pmc: PMC8358594
doi:
Types de publication
Journal Article
Langues
eng
Pagination
706Informations de copyright
Copyright: © Xie et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Bioinformatics. 2020 Jun 1;36(12):3749-3757
pubmed: 32227201
BMC Genomics. 2019 Mar 29;20(1):249
pubmed: 30922218
Nat Rev Clin Oncol. 2019 Jun;16(6):341-355
pubmed: 30718843
Trends Biochem Sci. 2018 Apr;43(4):301-310
pubmed: 29463470
Onco Targets Ther. 2020 Jan 31;13:945-958
pubmed: 32099398
Sci Rep. 2020 Oct 19;10(1):17597
pubmed: 33077815
Popul Health Manag. 2019 Feb;22(1):48-62
pubmed: 29889616
Cancer Cell Int. 2019 Aug 23;19:219
pubmed: 31462892
J Proteomics. 2019 Mar 30;196:106-119
pubmed: 30710758
Int Immunopharmacol. 2020 Jun;83:106478
pubmed: 32278132
Cancer Commun (Lond). 2020 Oct;40(10):518-530
pubmed: 32888253
Cell. 2020 Jul 9;182(1):245-261.e17
pubmed: 32649877
Int J Oncol. 2018 Apr;52(4):1081-1094
pubmed: 29484374
Lung Cancer. 2019 Jul;133:103-109
pubmed: 31200815
Methods Mol Biol. 2017;1525:137-164
pubmed: 27896721
Ann Oncol. 2020 Dec;31(12):1746-1754
pubmed: 32866624
J Proteome Res. 2020 Feb 7;19(2):973-983
pubmed: 31935107
Int J Mol Sci. 2020 Oct 22;21(21):
pubmed: 33105850
Semin Cell Dev Biol. 2017 Apr;64:73-78
pubmed: 27569189
Proteomics. 2019 Nov;19(21-22):e1800445
pubmed: 31172665
Int J Mol Sci. 2020 Oct 25;21(21):
pubmed: 33113782
J Transl Med. 2020 Jan 14;18(1):25
pubmed: 31937321
CA Cancer J Clin. 2016 May;66(3):175-6
pubmed: 26991239
Int J Med Sci. 2019 Aug 14;16(9):1199-1206
pubmed: 31588184
Theranostics. 2020 Aug 29;10(23):10838-10848
pubmed: 32929383
Lung Cancer. 2018 Feb;116:90-95
pubmed: 29413057
Int J Biol Sci. 2012;8(5):672-84
pubmed: 22606048
J Biol Chem. 2020 Feb 14;295(7):1992-2000
pubmed: 31831623
Adv Exp Med Biol. 2019;1134:259-269
pubmed: 30919342
Neuro Oncol. 2014 Jan;16(2):241-9
pubmed: 24335696
Genomics. 2020 Nov;112(6):4675-4683
pubmed: 32798715
Genes (Basel). 2020 Feb 14;11(2):
pubmed: 32075093
Cancer Sci. 2019 Sep;110(9):2734-2747
pubmed: 31278886
BMC Cancer. 2019 Apr 27;19(1):396
pubmed: 31029168
Expert Rev Proteomics. 2013 Jun;10(3):227-37
pubmed: 23777214
Chem Rev. 2016 Apr 27;116(8):4884-909
pubmed: 27074302
J Biol Chem. 2018 Feb 23;293(8):2675-2686
pubmed: 29348167
Cancer Res. 2015 Apr 15;75(8):1541-7
pubmed: 25836717
Sci Rep. 2020 Oct 30;10(1):18744
pubmed: 33127976
Cancer Med. 2019 Oct;8(13):5850-5861
pubmed: 31407494
Mol Oncol. 2019 Nov;13(11):2305-2328
pubmed: 31495056
CA Cancer J Clin. 2016 Jan-Feb;66(1):5-6
pubmed: 26595892
Lung Cancer. 2019 Aug;134:79-84
pubmed: 31320000
Haematologica. 2020 Jun;105(6):1712-1722
pubmed: 31399531
J Pathol. 2020 May;251(1):100-112
pubmed: 32154592